إعلان مُمول
Resmetirom Approval Marks a Milestone in MASH Treatment
Metabolic Dysfunction-Associated Steatohepatitis (MASH), previously known as Nonalcoholic Steatohepatitis (NASH), represents a progressive form of metabolic liver disease closely linked to obesity, type 2 diabetes, and insulin resistance. This reclassification under the broader Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) framework reflects a shift toward understanding liver...
0 التعليقات 0 المشاركات 73 مشاهدة 0 معاينة
إعلان مُمول
إعلان مُمول
إعلان مُمول